HEOR

News

ICER says GLP-1s 'still have serious affordability issues'

Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.

News

NHS cleared to use digital cardiac rehab programmes

Six digital cardiac rehabilitation programmes can be used by the NHS in England, but more data is needed on seven others, says NICE.

News

NHS cleared to use AZ's Fasenra for rare autoimmune disease

NICE backs NHS use of an AstraZeneca drug for one rare disease, but says it can't recommend a BioMarin therapy for another.

News

England poised to roll out drug for rare eye disease LHON

Patients in England with rare eye disorder LHON will finally get access to a Chiesi drug that has been available in the rest of the UK for years.

News

New medicines review process under NHS 10-Year Plan emerges

More details have emerged of a UK plan for new medicines to get simultaneous decisions from the MHRA and NICE on their use by the NHS.

News

NICE CEO to step down by year-end

Sam Roberts is stepping down from the role of NICE CEO to support her children through a difficult time, and a search for her replacement is underway.

ICER says GLP-1s 'still have serious affordability issues'

NHS cleared to use digital cardiac rehab programmes

NHS cleared to use AZ's Fasenra for rare autoimmune disease

England poised to roll out drug for rare eye disease LHON

New medicines review process under NHS 10-Year Plan emerges

NICE CEO to step down by year-end

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

HEOR

Editor's Picks